Report cover image

Dilated Cardiomyopathy Therapeutics Market by Drug class (Aldosterone antagonists, Angiotensin II Receptor Blockers, Angiotensin-converting enzyme (ACE) Inhibitors), Treatment Type (Cardioverter-Defibrillators, Heart Pumps, Implantable Devices), Route of

Publisher 360iResearch
Published Oct 04, 2023
Length 190 Pages
SKU # IRE18315893

Description

Dilated Cardiomyopathy Therapeutics Market by Drug class (Aldosterone antagonists, Angiotensin II Receptor Blockers, Angiotensin-converting enzyme (ACE) Inhibitors), Treatment Type (Cardioverter-Defibrillators, Heart Pumps, Implantable Devices), Route of Administration, End-User, Distribution Channel - Global Forecast 2023-2030


The Dilated Cardiomyopathy Therapeutics Market size was estimated at USD 389.65 million in 2022 and expected to reach USD 421.50 million in 2023, at a CAGR 7.83% to reach USD 712.65 million by 2030 .

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Dilated Cardiomyopathy Therapeutics Market.
  • Based on Drug class, market is studied across Aldosterone antagonists, Angiotensin II Receptor Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, and Beta-blockers. The Beta-blockers is projected to witness significant market share during forecast period.
  • Based on Treatment Type, market is studied across Cardioverter-Defibrillators, Heart Pumps, Implantable Devices, and Medication. The Cardioverter-Defibrillators is projected to witness significant market share during forecast period.
  • Based on Route of Administration, market is studied across Oral and Parenteral. The Oral is projected to witness significant market share during forecast period.
  • Based on End-User, market is studied across Hospitals, Research Institutes, and Specialty Clinics. The Hospitals is projected to witness significant market share during forecast period.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. The Hospital Pharmacy is projected to witness significant market share during forecast period.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Asia-Pacific is projected to witness significant market share during forecast period.
Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Dilated Cardiomyopathy Therapeutics Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Dilated Cardiomyopathy Therapeutics Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Dilated Cardiomyopathy Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Amicus Therapeutics, Astellas Pharma Inc, AstraZeneca plc, Bayer AG, Biogen Inc., BioMarin Pharmaceutical Inc, C.H. Boehringer Sohn AG & Co. KG, Daiichi Sankyo Company, Limited, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline (GSK), Johnson & Johnson Services, Inc., Kyowa Kirin Co, Ltd, Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., Sarepta Therapeutics, Teva Pharmaceutical Industries Ltd., The Bristol-Myers Squibb Company, The Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals, and Viatris Inc..

The report offers valuable insights on the following aspects:
  1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
  2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
  3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
  4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
  5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
  1. What is the market size and forecast for the Dilated Cardiomyopathy Therapeutics Market?
  2. Which products, segments, applications, and areas hold the highest investment potential in the Dilated Cardiomyopathy Therapeutics Market?
  3. What is the competitive strategic window for identifying opportunities in the Dilated Cardiomyopathy Therapeutics Market?
  4. What are the latest technology trends and regulatory frameworks in the Dilated Cardiomyopathy Therapeutics Market?
  5. What is the market share of the leading vendors in the Dilated Cardiomyopathy Therapeutics Market?
  6. Which modes and strategic moves are suitable for entering the Dilated Cardiomyopathy Therapeutics Market?


Note: PDF & Excel + Online Access - 1 Year

Table of Contents

190 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Dilated Cardiomyopathy Therapeutics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of cardiovascular diseases and the need for effective treatments
5.1.1.2. Inclination toward early diagnosis and treatment of diseases
5.1.1.3. Government initiatives and programs to raise awareness regarding cardiovascular diseases
5.1.2. Restraints
5.1.2.1. High cost of dilated-cardiomyopathy therapeutics
5.1.3. Opportunities
5.1.3.1. Applications of precision medicine in the management of dilated cardiomyopathy
5.1.3.2. Ongoing R&D for the development of efficient drugs and therapies for dilated-cardiomyopathy
5.1.4. Challenges
5.1.4.1. Side effects associated with the dilated-cardiomyopathy medications
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Dilated Cardiomyopathy Therapeutics Market, by Drug class
6.1. Introduction
6.2. Aldosterone antagonists
6.3. Angiotensin II Receptor Blockers
6.4. Angiotensin-converting enzyme (ACE) Inhibitors
6.5. Beta-blockers
7. Dilated Cardiomyopathy Therapeutics Market, by Treatment Type
7.1. Introduction
7.2. Cardioverter-Defibrillators
7.3. Heart Pumps
7.4. Implantable Devices
7.5. Medication
8. Dilated Cardiomyopathy Therapeutics Market, by Route of Administration
8.1. Introduction
8.2. Oral
8.3. Parenteral
9. Dilated Cardiomyopathy Therapeutics Market, by End-User
9.1. Introduction
9.2. Hospitals
9.3. Research Institutes
9.4. Specialty Clinics
10. Dilated Cardiomyopathy Therapeutics Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Americas Dilated Cardiomyopathy Therapeutics Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Dilated Cardiomyopathy Therapeutics Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Dilated Cardiomyopathy Therapeutics Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. AbbVie Inc.
15.1.2. Amgen Inc.
15.1.3. Amicus Therapeutics
15.1.4. Astellas Pharma Inc
15.1.5. AstraZeneca plc
15.1.6. Bayer AG
15.1.7. Biogen Inc.
15.1.8. BioMarin Pharmaceutical Inc
15.1.9. C.H. Boehringer Sohn AG & Co. KG
15.1.10. Daiichi Sankyo Company, Limited
15.1.11. Eli Lilly and Company
15.1.12. Gilead Sciences, Inc.
15.1.13. GlaxoSmithKline (GSK)
15.1.14. Johnson & Johnson Services, Inc.
15.1.15. Kyowa Kirin Co, Ltd
15.1.16. Merck & Co., Inc.
15.1.17. Novartis AG
15.1.18. Pfizer Inc.
15.1.19. Regeneron Pharmaceuticals, Inc.
15.1.20. Roche Holding AG
15.1.21. Sanofi S.A.
15.1.22. Sarepta Therapeutics
15.1.23. Teva Pharmaceutical Industries Ltd.
15.1.24. The Bristol-Myers Squibb Company
15.1.25. The Takeda Pharmaceutical Company Limited
15.1.26. Vertex Pharmaceuticals
15.1.27. Viatris Inc.
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us